Clinical trials: Hematological Neoplasm
Tumors, Malignant Melanoma
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
The purpose of this research study is to evaluate the effectiveness of transplantation of high doses of peripheral blood stem cells (stem cells are special cells found in the blood and bone marrow that produce new blood cells)…
- Conditions
- Tumors, Malignant Melanoma, Hematological Malignancies, Myelogenous Leukemia, Chronic
- Trial name
- NCT00179764
- Testing
- Immunoablative Hematopoietic PBSC Transplant, Busulfan pharmacokinetics, Central Nervous System (CNS) prophylaxis radiation
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Platelet Transfusion, Hematological Malignancy
Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)
Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its…
- Conditions
- Platelet Transfusion, Hematological Malignancy, Palliative Care
- Trial name
- R-PLQ (NCT03806712)
- Testing
- multi method questionary (developped by De Rosa, in 1995 and 2014)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Relapsed or Refractory Hematological Malignancies
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.
- Trial name
- NCT04011293
- Testing
- CNCT19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong University
Cancer and / or Hematological Malignancy
Cohort of Patients Over 70 Years of Age With Cancer and / or Hematological Malignancy
Follow-up of patients> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions.
- Trial name
- ChimioAge (NCT03960593)
- Testing
- Evaluation of the influence of geriatric factors
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hematological Malignancy
MS Detection of Somatic Mutations in Hematological Malignancies
Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limitation for its availability.
- Trial name
- MAHM (NCT03771079)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Hematological Cancer
MethylphenIdate for Fatigue in Haematological Cancer
Cancer related fatigue (CRF) is the most debilitating problem for patients with haematological cancer. CRF severely reduces quality of life (QoL), functional capacity, impacts health behavior, recovery and furthermore no approved…
- Trial name
- MICRO (NCT03218254)
- Testing
- Methylphenidate
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Henrik Frederiksen
Antibacterial Prophylaxis, Hematological Malignancies
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies.
- Conditions
- Antibacterial Prophylaxis, Hematological Malignancies, Allogenetic Hematopoietic Stem Cell Transplantation, Imipenem
- Trial name
- NCT03733340
- Testing
- Imipenem
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematological Malignancies
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic…
- Trial name
- NCT00047489
- Testing
- ABT-751
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancy
Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers
This study will address whether teaching the Body Scan exercise to cancer patients with hematological malignancies and their caregivers during an inpatient hospitalization improves reported physical and psychological symptoms…
- Trial name
- NCT03611764
- Testing
- Body Scan, Rotterdam Symptom Checklist, Practice Logs
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hematological Malignancies
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer.
- Trial name
- NCT00824993
- Testing
- Ibandronate, Vitamin Supplements
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancer, Hematological Malignancy
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
The emergence of oral delivery in cancer therapeutics is expected to result in an increased need for better coordination between all treatment stakeholders, mainly to ensure adequate treatment delivery to the patient.
- Trial name
- CAPRI (NCT02828462)
- Testing
- CAPRI
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hematological Malignancies
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity…
- Trial name
- NCT01139164
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Medical University of South Carolina
Hematological Malignancies
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients…
- Trial name
- NCT01246206
- Testing
- Tacrolimus and Thymoglobulin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Relapse of Hematological Malignancies
Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT
Relapse of underlying hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) is frequently treated by a second allogeneic HSCT (HSCT2).
- Trial name
- NCT01997918
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Hematological Malignancies
Impact of Child Positioning on Pain During a Lumbar Puncture
This protocol is a pilot study on standard care. The main goal is to assess the impact of positioning on lumbar puncture process especially on pain sensitivity in children.
- Trial name
- PHIPA-PEPL (NCT02834156)
- Testing
- LP in a seated position then LP in a lying position, LP in a lying position then LP in a seated position
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
- Trial name
- CLC-102 (NCT02223598)
- Testing
- CB-5083, Dexamethasone
- Where
- 8 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Cleave Biosciences, Inc.
Hematological Malignancies
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
Allogeneic stem cell transplantation offers the hope of cure for a wide variety of hematologic malignancies. Mature donor T-cells play a critical role in the success or failure of this procedure and a subset of donor T-cells…
- Trial name
- NCT01627275
- Testing
- Naive T Cell Depleted Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mitchell Horwitz, MD
Hematological Malignancies
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Trial name
- NCT02199041
- Testing
- Cyclophosphamide, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Hematological Malignancy, Bone Marrow Failure Syndrome
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant…
- Trial name
- NCT00897260
- Testing
- Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Leukemia, Acute Leukemia
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after…
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00701844
- Testing
- Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing)
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- University of North Carolina, Chapel Hill